The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after 12 months. BridgeBio’s base case and upside targets for the muscle damage ...
Pleural Dynamics Announces Completion of Enrollment of “The ACES Study for Aseptic Pleural Effusions,” a Post Market Study Evaluating the Novel ACES Automatic Continuous Effusion Shunt System Pleural ...
MINNEAPOLIS--(BUSINESS WIRE)--Pleural Dynamics, a medical device company that is building solutions for recurrent fluid collections in the body, announced today that the final patient in “The ACES™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback